Pay in 4 interest-free payments of $5.16 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
June 22 Product: Bristol Myers Squibbs Krazati Indication: Colorectal cancer Bristol Myers Squibbs oncology franchise is celebrating another approval after the FDA greenlit Krazati in combination with cetuximab for patients with previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer
Take care: Keep the spray pump clean and refrigerated at all times to prevent contamination and peptide degradation
But the strength of the evidence varies enormously according to the molecule, the formulation and the route of administration
Key Takeaways Muscle cramps aren't known to be a direct side effect of GLP-1 medications, but dehydration, GI symptoms, and reduced food intake can contribute to them
